

# Cyclin D1 Gene Expression in Oral Mucosa of Tobacco Chewers”–An Immunohistochemical Study

MAHARUDRAPPA BASNAKER<sup>1</sup>, SRIKALA SP<sup>2</sup>, SATISH BNVS<sup>3</sup>

## ABSTRACT

**Objective:** The objective of the present study was to evaluate the expression of cyclin D1 in normal oral mucosa of both non tobacco habituated and tobacco habituated individuals histologically and also compare and correlate cyclin D1 expression with histopathologically confirmed cases of oral squamous cell carcinomas.

**Study Design:** The present study involved 20 cases of tobacco habituated individuals with normal oral mucosal tissue and 20 histopathologically confirmed cases of squamous cells carcinomas. Twelve cases of non tobacco habituated individuals served as control group. Chi-square analysis was used to determine statistical significance.

**Results:** Fifty percent of control cases, 70% of squamous cell carcinoma cases and 80% of tobacco habituated individuals of clinically normal mucosa showed cyclin D1 positivity. Thirteen cases with tobacco chewing habit, with clinically normal mucosa, showed dysplasia, out of which seven were mildly dysplastic and six were moderately dysplastic. A larger

percentage of cyclin D1 expression was observed in lower grade dysplasias (53.8%) than higher grade dysplasias (46.1%). However statistical analysis showed no significant association between groups. Chi-square value was  $< 7.82$  for  $p=0.05$ .

**Conclusion:** The finding of cyclin D1 expression in 80% of tobacco users with clinically normal mucosa indicates that the mutation of cyclin D1 occurs early, even before clinical changes are apparent. This finding appears to be previously unreported. The presence of dysplasia in the same group and cyclin D1 expression in 84.6% of dysplastic cases show that the patients are susceptible for further changes, including progression to higher grades of dysplasia and development of carcinoma. Relatively lower expression of cyclin D1 positivity (70%), in oral cancer patients, when compared with tobacco users with clinically normal mucosa (80%) is indicative of increased traverse of the cell through the cell cycle, which may occur early in tumor progression. Cyclin D1 immunoreactivity was detected in all the three study groups.

**Keywords:** Oral cancer, Cyclin D1, Immunohistochemistry, normal oral mucosa, Tobacco chewers, Epithelial dysplasia

## INTRODUCTION

Oral cancer is one of the leading causes of death in India and south east Asia. Squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. In Indian subcontinent oral cancer is mainly due to chewing tobacco and tobacco related products [1].

The orderly progression of the cells through the different phase of cell cycle is precisely governed by a series of proteins called “cyclins”, whose influence effect the binding and activation of the cyclin dependent kinases (CDK). This process is further regulated by phosphorylation, tumor suppressor genes and inhibited by cyclin dependent kinase inhibitors [2]. Dysregulation of the cell cycle mechanism is a critical event in carcinogenesis and it is emerging as a central theme in oral carcinogenesis. The genes involved in cell cycle regulation represent targets of oncogenic abnormalities among which Cyclin D1 is most involved [2].

Cyclin D1 is a 45 KD (Kilo Dalton) protein. It is a proto-oncogene, encoded by CCND1, located on chromosome 11q13. It is a part of the molecular system that expresses and regulates the cell cycle from G1 phase to S phase of cell cycle transition [3]. It was first isolated as PRAD1 (parathyroid adenomatosis 1 gene) oncogene clonally rearranged and over expressed in parathyroid adenomas and was identical to bcl-1 (B-cell lymphoma 1 gene) proto oncogene, which is translocated and over expressed in a subset of B-cell neoplasms [4]. Over expression of Cyclin D1 leads to shortening of G1 phase and less dependency on growth factors resulting in abnormal cell proliferation which in turn favours the occurrence of additional genetic lesions [5].

Studies involving oral squamous cell carcinomas with cyclin D1 are few. [6–16] and some are carried out to correlate the expression of cyclin D1 with histological grading of these neoplasms [1,11,14,17]. However the results have not been consistent and conclusive.

Though tobacco is the most important factor in the causation of the oral squamous cell carcinoma, the expression of cyclin D1 in clinically normal oral mucosa of tobacco habituated individuals has not been studied. The present study is undertaken to fill the void in this important field.

## MATERIALS AND METHODS

The patients and tissue samples for the present study were taken from those attending the Out Patient Department (OPD) of S. Nijalingappa Institute of Dental Sciences and research Gulbarga. The subjects involved belonged to different sections of the society of Northeast Karnataka, India The following inclusion and exclusion criteria were considered for the present study.

### Exclusion Criteria

Oral mucosal lesions like, Leukoplakia, Erythroplakia, Oral submucous Fibrosis and patients undergoing radiation and chemotherapy were excluded from the study.

### Inclusion Criteria

Tobacco habituated individuals, Non tobacco habituated individual, and Oral cancer patients of both the genders were included in the present study. The present study consisted of three category of subjects.

Group-I, Twelve patients without tobacco chewing or smoking habits with clinically normal oral mucosa served as control cases.

Group-II, Twenty patients with tobacco chewing or smoking habits but with clinically normal oral mucosa.

Group-III, Twenty patients of clinically and Histopathologically confirmed cases of oral squamous cell carcinoma with the habit of tobacco chewing and smoking.

The tissue, representative of lesional area were obtained from all the study group patients by incisional or excisional biopsy. Informed and written consent was taken from the patients. The use of human tissue samples was approved by the institutional ethical committee.

#### Methods for Haematoxylin and eosin staining

Formalin fixed, paraffin embedded tissue samples were cut into 5micron sections. The sections were deparaffinised in xylene, rehydrated through graded alcohol. One section was stained for haematoxylin and eosin subsequently mounted under DPX. The Other section was used for immunohistochemical staining.

#### Immunohistochemical staining-procedure

5  $\mu$  sections of formalin fixed, paraffin embedded tissue samples were cut and placed on clean electrostatically charged glass slides. The sections were dried overnight in a 37°C incubator. Subsequently sections were dewaxed in xylene. (10 min, 2 changes) and dehydrated in absolute alcohol. The sections were then rehydrated in Propanol (10 min 2 changes) and then washed well in running water. Antigen was retrieved by using 2 litre domestic stainless steel pressure cooker using trisodium citrate buffer. Then the slides were transferred to tris buffered saline (TBS) for 5 minutes twice and subsequently covered with peroxide block (HK111) reagent. The sections are incubated for 10 minutes at room temperature in humid chamber and rinsed well with buffer wash for 5 minute, twice. The tissues were then covered with power block (HK083) reagent and incubated for 5-10 minutes at room temperature in humid chamber. The tissues were then gently blotted. Tissues were covered with primary antibody (Biogenex rabbit monoclonal antibody). Likewise, negative control serum (HK408) was added to the negative control slide. The slides were incubated for 1 hour at room temperature in humid chamber and rinsed well with wash buffer for 5 minute twice. The recommended positive control tissue is thyroid carcinoma tissue. Tissues were covered with super enhancer (HK518) and incubated for 20 minutes at room temperature in humid chamber. The slides were then rinsed well with wash buffer for 5 minute twice. Sections were covered with polymer HRP (HK519) reagent and incubated for 30 minutes, at room temperature in humid chamber. The slides were then rinsed well with wash buffer for 5 minute twice. Tissues were covered with Substrate Solution (One drop of DAB chromogen (HK124) mixed with 1 ml of substrate buffer (HK520) and incubated for 10 minutes, at room temperature in humid chamber. The slides were rinsed well with wash buffer. The sections were counterstained with haematoxylin, dehydrated, cleared and mounted. The insoluble, permanent brown precipitate formed at the site of antigen (nucleus) was interpreted as positive. The intensity of staining was graded as either negative or positive. The positive intensity of staining is graded as '+' weak, '++' moderate, '+++'' intense, absence of staining, '-ve'.

#### STATISTICAL ANALYSIS

Chi-square analysis was used to test the immunohistochemical expression of cyclin D1 with different parameters. Statistical significance was set at  $p \leq 0.05$ .

#### RESULTS

Six cases of the control group (12 cases) of healthy individuals with normal mucosa did not express cyclin D1, [Table/Fig-1,2] and six cases expressed cyclin D1 in the basal and parabasal layers, of which 2 cases showed weak intensity and 4 cases showed moderate intensity of immunostaining. In tobacco users with

clinically normal mucosa, 80% (16/20 cases) expressed cyclin D1. Seven of the twenty cases showed mild dysplasia, of which 6 were positive for cyclin D1, four cases showed moderate intensity and 2 cases showed intense intensity of immunostaining. Six of the twenty cases showed moderate dysplasia, of which five cases were positive for cyclin D1, one case showed weak intensity, two cases showed moderate intensity and two cases showed intense intensity of immunostaining. Cyclin D1 expression in dysplastic lesions is 84.6% (11/20) and a larger percentage of cyclin D1 expression was observed in lower grade dysplasias (53.8%) than higher grade dysplasias (46.1%) [Table/Fig-3,4].

In oral cancer patients 70% (14/20 cases) showed cyclin D1 expression. Fifteen of the twenty cases were well differentiated, four were moderately differentiated and one was poorly differentiated squamous cell carcinoma. Out of fifteen cases of well differentiated squamous cell carcinomas, four cases showed weak intensity, one case showed moderate intensity and four cases showed intense intensity of immunostaining. Out of four cases of moderately differentiated squamous cell carcinomas, one case showed weak intensity, one case moderate intensity and two case intense intensity of immunostaining with cyclin D1. One case of poorly differentiated squamous cell carcinoma showed moderate intensity of immunostaining [Table/Fig-5,6].

The slides stained by haematoxylin and eosin were classified according to the histological malignancy grading system proposed by Border [18]. Histopathological evaluation was reported by two independent senior oral pathologists.


#### DISCUSSION

The high incidence of cancers is due to various intrinsic and extrinsic factors. Of the extrinsic factors tobacco is the most important agent. Tobacco smoke is responsible for 80-90 % of the lung cancer cases, [19] and significant percentages of cancers of oral cavity, larynx, oesophagus, pancreas, kidney, bladder and cervix [20].

Cigarette smoke contains at least 3,500 unidentified chemical constituents, nearly 40 % of them being carcinogenic like polycyclic aromatic hydrocarbons (PAH), such as benzo (a) pyrene (Bap), and 4 (N - methyl nitrosoamino) - 1 - (3-pyridil) -1- butanone (NNK), are the important carcinogens. Relatively fewer carcinogens are present in smokeless tobacco. About 30 carcinogens have been identified, the major contributor being nicotine derived nitrosamines (TSNA). Smokeless tobacco is often combined with other reagents including betel leaf, sliced arecanut and powdered slaked lime. These additives used not only enhance the psychotropic effects of nicotine but also make the combination more genotoxic than the tobacco alone [21].

Sl No.	Age years	Sex	Cyclin D1 expression
1. S-330/13	55	Male	-ve
2. S-328/13	28	Male	+
3. S-264/13	35	Male	++
4. S-258/13	50	Female	++
5. S-185/13	47	Male	+
6. S-187/13	38	Male	-ve
7. S-237/13	28	Female	-ve
8. S-256/13	45	Male	++
9. S-259/13	28	Male	++
10. S-242/13	34	Male	-ve
11. S-254/13	48	Male	-ve
12. S-347/13	42	Male	-ve

[Table/Fig-1]: APPENDIX – I: Cyclin D1 expression in oral biopsies of normal oral mucosa of individuals without habit of tobacco chewing and smoking



**[Table/Fig-2]:** Normal oral epithelium stained weakly with cyclin D1 (100X) Weakly stained cells for cyclin D1 (↑) GROUP – I cases

factors [25]. This may contribute to disturbance in the normal cell cycle control and mitogenic signaling pathways, enhancing the cell transformation and tumorigenicity [2]. Thus, overexpression of cyclin D1 is thought to provide the tumor cells with a selective growth advantage [26]. The mechanisms underlying cyclin D1 overexpression include gene amplification [27], chromosomal inversion, translocations [5,28,29] transcriptional i.e. upregulation of gene transcription, [30] and posttranscriptional mechanisms [2]. In general, mutations of cyclin D1 gene results in abnormal accumulation of protein, which being much more metabolically stable than the wild protein type, accumulates in the nucleus, reaching the threshold of immunohistochemical detection. Therefore, immunohistochemical demonstration of abnormal presence of cyclin D1 gene product in histological sections of neoplasms may be regarded as an indication of possible mutation of cyclin D1 gene itself.

Over expression of cyclin D1 has been reported in breast carcinomas [31] colon carcinomas, [28] oesophageal carcinomas, [27] head and neck carcinomas, [32] etc. and its overexpression has been correlated

Case No.	Age years	Sex	Tobacco Habit* Smoking(S), Chewing (C)	Dysplasia Grade**	Cyclin D1 expression***
1. S-261/13	33	Male	Heavy (c)	ND	+++
2. S-262/13	52	Male	Heavy (S+C)	Mild	+++
3. S-265/13	28	Male	Heavy (c)	Moderate	++
4. S-245/13	49	Male	Heavy (S+C)	Moderate	+++
5. S-243/13	42	Male	Heavy (S+C)	Moderate	+++
6. S-267/13	27	Male	Moderate(C)	ND	+
7. S-251/13	23	Male	Moderate(C)	ND	-ve
8. S-300/13	32	Male	Moderate(S+C)	ND	-ve
9. S-334/13	23	Male	Moderate(C)	ND	+++
10. S-295/13	31	Male	Moderate(C)	Mild	++
11. S-325/13	32	Male	Heavy (C)	ND	++
12. S-312/13	35	Male	Heavy (S+C)	Mild	++
13. S-332/13	24	Male	Heavy (C)	Mild	++
14. S-270/13	27	Male	Heavy (S+C)	Moderate	-ve
15. S-319/13	44	Male	Heavy (C)	Mild	-ve
16. S-292/13	45	Female	Heavy (C)	ND	++
17. S-306/13	65	Male	Heavy (S+C)	Moderate	+
18. S-286/13	30	Male	Moderate(S+C)	Mild	+++
19. S-318/13	55	Male	Heavy (S+C)	Mild	++
20. S-272/13	45	Male	Moderate(C)	Moderate	++

**[Table/Fig-3]:** APPENDIX – II: Cyclin D1 expressions in oral biopsies of tobacco users with clinically normal oral mucosa

Note: \* Tobacco use: (1) Moderate - Chewing tobacco less than 10 packets daily for less than 10 years or smoking less than twenty bidis/cigarettes for less than 10 years. (2) Heavy - Chewing tobacco more than 10 packets daily for more than 10 years or more than 20 bidis/cigarettes for more than 10 years. \*\* Dysplasia Grade: Mild, moderate, severe, no dysplasia (ND). \*\*\*cyclin D1 expression, intensity of staining. '+' weak, '++' moderate, '+++' intense, absence of staining, '-ve'

All smokeless tobacco products are buffered to facilitate nicotine absorption through the oral mucosa [22].


The various mechanisms of smokeless tobacco induced carcinogenesis include sister chromatid exchange (SCE), chromosomal aberrations and formation of micro nucleus. The various tobacco products after metabolism in the liver form DNA adducts and cause mutations in vital genes like Rb, P53, K ras etc and also interfere with DNA repair. Haemoglobin adduct formation with tobacco and arecanut extracts like arecoline have been reported [23].

Oncogenes, tumor suppressor genes, viral products and cell cycle related factors are important factors in carcinogenesis. As many as six to ten genetic alterations are involved in the development of head and neck cancer [24]. Escape of cancer cells from the cell cycle machinery reflects a fundamental hallmark of cancer progression and is even emerging as a central theme in oral carcinogenesis [2]. Overexpression of cyclin D1 may lead to shortening of the G1 phase, increased cell proliferation, and reduced dependency on growth

to advanced clinical stage, [33] poor prognosis, [32], 8(8,32) increased risk of recurrence [15] and lymph node metastasis. [6,7,34] A few studies have been carried out to correlate cyclin D1 expression with tobacco use, [9] areca quid chewing and poor prognosis, [10] different degrees of dysplasias and SCC, [12] cisplatin resistance, [13] cyclin dependant kinases [16] in oral squamous cell carcinomas and some have been carried out to correlate the expression of cyclin D1 with histological grading of this neoplasm [1,11,14,17]. However some authors found no clinical correlation [35,36]. Over expression of cyclin D1 was seen to be positively correlating with other proliferation markers such as Ki-67, proliferating cell nuclear antigen (PCNA), and other cell cycle regulatory proteins such as CDK4, P21, E2F1 and P53. The above mentioned studies support the role of cyclin D1 as a potential marker of proliferation and oncogenesis.

In this present study cyclin D1 expression is studied by immunohistochemical method using Biogenics rabbit monoclonal antibody in tobacco users with clinically normal mucosa and oral cancer patients habituated to tobacco. The result are compared with





**[Table/Fig-4]:** Intensely stained oral epithelium cells of Tobacco chewers with cyclin D1 (100X) Intensely stained cells for cyclin D1 (↑) GROUP – II cases

the basal and parabasal layers of normal mucosa [38–40] [Table/Fig-1,2].

In the present study cyclin D1 expression was found to be positive in 16 (80%) of the 20 cases of tobacco users with clinically normal mucosa. No epithelial dysplasia was observed in 7 cases of tobacco users with clinically normal mucosa. Remaining 13 cases showed dysplasia, out of which 7 cases were mildly dysplastic, 6 cases were moderately dysplastic. The expression of cyclin D1 in a majority of tobacco users – smokeless with or without smoking shows the effect of tobacco insult on protooncogenes before clinical alterations are evident and lends credence to the concept that mutation of cyclin D1 protein occur in the early phase of oral carcinogenesis. The expression of cyclin D1 in epithelial dysplasia, though variable from 8.6 % to 82.4 %, [12,41] our results of 84.6 % of a very small sample is quite consistent. Overexpression of cyclin D1 expression is seen in 53.8 % of mild, and 46.1 % of moderate oral epithelial dysplasia, which is consistent with previous studies [40,41] [Table/Fig-2,5].

Case No	Age years	Sex	TNM staging	Histological grade*	Site**	Tobacco Habit***	Cyclin D1 expression***
1. S-299/13	65	Male	T <sub>4</sub> N <sub>0</sub> M <sub>0</sub> (IV)	WD	P	Moderate (C+S)	-ve
2. S-225/13	70	Female	T <sub>4</sub> N <sub>0</sub> M <sub>0</sub> (IV)	MD	P	Moderate (C)	+++
3. S-230/13	38	Male	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	MBS	Heavy (C)	-ve
4. S-110/13	58	Male	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	MBS	Heavy (C)	+
5. S-27/12	50	Male	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	T	Heavy (C) Moderate (S)	+++
6. S-12/12	45	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	PD	BM	Heavy (C)	++
7. S-44/13	37	Male	T <sub>3</sub> N <sub>0</sub> M <sub>0</sub> (III)	WD	MBS	Moderate (C)	+++
8. S-196/12	60	Male	T <sub>1</sub> N <sub>0</sub> M <sub>0</sub> (I)	WD	P	Moderate (C) Heavy (S)	+++
9. S-286/12	30	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	MD	LAM	Heavy (C)	+++
10. S-127/11	60	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	LMAG	Moderate (C) Heavy (S)	+
11. S-162/11	32	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	T	Moderate (C)	-ve
12. S-107/11	39	Male	T <sub>4</sub> N <sub>0</sub> M <sub>0</sub> (IV)	WD	BM	Moderate (C)	+++
13. S-47/13	45	Male	T <sub>2</sub> N <sub>1</sub> M <sub>0</sub> (II)	WD	LAM	Heavy (C)	-ve
14. S-92/11	50	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	BM	Moderate (C+S)	+
15. S-91/11	50	Male	T <sub>3</sub> N <sub>0</sub> M <sub>0</sub> (III)	WD	BM	Moderate (C+S)	-ve
16. S-74/11	50	Female	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	RMA	Heavy (C)	++
17. S-54/11	54	Male	T <sub>2</sub> N <sub>0</sub> M <sub>0</sub> (II)	WD	BM	Moderate (C)	-ve
18. S-74/13	45	Male	T <sub>1</sub> N <sub>0</sub> M <sub>0</sub> (I)	WD	T	Moderate (C+S)	+
19. S-59/13	58	Female	T <sub>2</sub> N <sub>1</sub> M <sub>0</sub> (III)	MD	T	Moderate (C)	++
20. S-60/13	62	Male	T <sub>1</sub> N <sub>0</sub> M <sub>0</sub> (I)	MD	LLM	Heavy (c+S)	+


**[Table/Fig-5]:** APPENDIX – III: Cyclin D1 expression in oral mucosal biopsies of histopathologically confirmed cases of oral squamous cell carcinoma  
 Note: \* Histological grade: Moderately differentiated (MD), Well differentiated (WD), Poorly differentiated (PD), (Broders grading). \*\* Site: Buccal Mucosa (BM), Tongue (T), Palate (P), Lower Alveolar Mucosa (LAM), Lower Lip (LL), Mandibular buccal sulcus(MBS), Lower marginal and attached gingival(LMAG), Retromolar area(RMA), Lower labial mucosa(LLM). \*\*\* Tobacco Habit & Cyclin D1 expression as in Appendix - II.

immunohistochemically stained sections of twelve control subjects. Cyclin D1 expressions was not observed in six of the control cases. This is consistent with previous studies of total absence of cyclin D1 expressions in normal oral mucosal biopsies [1,12,37]. The absence of cyclin D1 expression in normal individuals could be attributed to the short half life of wild type cyclin D1 protein, hence unable to detect by immunohistochemical methods. Half life of cyclin D1 protein is usually, 24 minutes [24]. Cyclin D1-3, Cyclin E bind with CDK 4 and 6 and CDK 2 respectively, and regulate transition from G1 to S phase. On completion of this task which requires about 24 min, cyclins decline rapidly and hence could not be detected immunohistochemically [25].

Six of the control cases showed cyclin D1 expression in nuclei of cells in the basal and parabasal epithelial layers consistent with the proliferative compartment of stratified squamous epithelium and it indicates that the cells are in G1- S transition phase of cell cycle. This is consistent with previous study of cyclin D1 expression in

The progression of the disease in the present study increased from early age to older age in the group- III cases. In the group -II cases, 55 percentage of cases were positive for cyclin D1 (11/20 cases), in the early age group i.e second to third decade of life is indicative of the fact that the individuals were susceptible to the genotoxic effects of tobacco and its related products, leading to the conclusion that the disease process being active at cellular and molecular level even before the apparent clinical changes are manifested. In the control group cases the expression was observed in all the age group patients in basal and supra basal layers, indicative of active cell proliferation in these cell layers.

In the present study expression of Cyclin D1 is observed in 14 of the 20 cases (70%) of histopathological confirmed cases of oral squamous cell carcinoma cases with tobacco habituation. Though cyclin D1 expression was observed by all workers in oral cancer biopsies, with the expression varying from 32% to 88.5%, the results of 70 % cyclin D1 expression in this study is consistent with previous studies



**[Table/Fig-6]:** Intensely stained squamous cell carcinoma with cyclin D1 (100X) Intensely stained cells for Cyclin D1(↑) GROUP – III cases

[12,32,39,42]. The higher expression of cyclin D1 can be attributed to the intensity, duration and form of tobacco used and the peculiar Indian habit of smokeless tobacco use. All the patients in this study were tobacco users of smoking and smokeless tobacco along with betel leaf and arecanut, of at least 10 years duration and above. Thus the high incidence could be explained due to combined effect of tobacco smoke, chewing tobacco and arecanut which is proved to be genotoxic [Table/Fig-5,6].

Most of the well differentiated squamous cell carcinomas showed cyclin D1 expression largely confined to the periphery of tumour nests consistent with the basal cells of tumor nests.

The percentage of cyclin D1 expression in carcinomas (70%) was reduced in comparison with the percentage of dysplastic lesions (84.6%) and we also found a larger percentage of cyclin D1 expression in lower grade dysplasias (53.8%) than higher grade dysplasias (46.1%) and squamous cell carcinomas (70%), which may be indicative of increased traverse through the cell cycle, occurring early in tumor progression [41].

With regard to cyclin D1 expression and grading in oral squamous cell carcinoma cyclin D1 expression increased with decrease in differentiation [1,11]. Since four cases, in this study belonged to moderately differentiated squamous cell carcinoma, 15 belonged to well differentiated squamous cell carcinoma and only one belonged to poorly differentiated squamous cell carcinoma, association between cyclin D1 expression and histological grades is not found statistically.

Over expression of cyclin D1 was significantly associated with regional lymph node metastases and advanced tumor stage [33]. Since three cases belonged to stage I, stage III and stage IV each, 11 cases belonged to stage II the association of cyclin D1 to different stages could also not be found statistically.

Though, there have been many studies of cyclin D1 expression on oral biopsies of squamous cell carcinoma, [3,7-16] the expression of cyclin D1 in clinically normal oral mucosa of tobacco habituated individuals has not been studied.

However, a study of a large samples of oral cancer cases and tobacco users with clinically normal mucosa cases by biopsies is needed to corroborate our findings.

## REFERENCES

- [1] Mishra R, Das BR. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. *Arch Oral Biol.* 2009; 54(10):917-23.
- [2] Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OS, Seliman Y, et al. Cell cycle dysregulation in oral cancer. *Crit Rev Oral Biol Med.* 2002; 13(1):51-61.
- [3] Kumar V, Cotran RS, Robbins SL. Robbins Basic Pathology, 7th ed. Pennsylvania: W B Saunders Company; 2003:187-192.
- [4] Hosokawa Y, Arnold A. Cyclin D1/PRAD1 as central target in oncogenes. *J Lab Clin Med.* 1996; 127:246-52.

- [5] Fracchiolla NS, Pruneri G, Pignataro L, Carboni N, Capaccio P, Boletini A, et al. Molecular and immunohistochemical analysis of the bcl-1 / Cyclin D1 gene in laryngeal squamous cell carcinomas. *Cancer.* 1997; 79:1114-21.
- [6] Lim SC, Zhang S, Ishii G, Endoh Y, Kodama K, Miyamoto S, et al. Predictive markers for late cervical metastasis in stage i and ii invasive squamous cell carcinoma of the oral tongue. *Clin Cancer Res.* 2004; 10:166-72.
- [7] Myo K, Uzawa N, Miyamoto R, Sonoda I, Yuki Y, Amagasa T. Cyclin D1 gene numerical aberration is a predictive marker for occult cervical lymph node metastasis in tm stage i and ii squamous cell carcinoma of the oral cavity. *Cancer.* 2005;104:2709-16.
- [8] Staibano S, Migonogua MD, Muzio LL, Alberti LD, Natale ED, Lucariello A, et al. Over expression of cyclin D1, bcl-2 and bax proteins; proliferating cell nuclear antigen, and DNA-ploidy in squamous cell carcinoma of the oral cavity. *Human Pathol.* 1998; 29(11):1189-94.
- [9] Jie Xu, Gimenez CIB, Cunningham JE, Collet AM, Luna MA, Lanfranchi HE, et al. Alterations of p53, Cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. *Cancer.* 1998; 83(2):204-12.
- [10] Kuo MYP, Lin CY, Hahn LJ, Cheng SJ, Chiang CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing related oral squamous cell carcinomas in Taiwan. *J Oral Pathol Med.* 1999; 28:165-9.
- [11] Neves AC, Mesquita RA, Novelli MD, Todda E, De Sousa SOM. Comparison between immunohistochemical expression of Cyclin D1 and p21 and histological malignancy graduation of oral squamous cell carcinomas. *J Braz Dent.* 2004; 15(2): 93-8.
- [12] Turrati E, Neves AC, Magalhaes MHCG, souse SOM. Assessment of c-Jun, c-Fos and Cyclin D1 in premalignant and malignant lesion. *J Oral Sci.* 2005 Jun;47(2):71-6.
- [13] Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. *BMC Cancer.* 2006;6:224-35.
- [14] Angadi PV, Krishnapillai R. Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;103:e30-5.
- [15] Miyamoto R, Uzawa N, Nagaoka S, Hiratay Amagasa T. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinoma. *Oral Oncol.* 2003; 39:610-8.
- [16] Woods M, Pant R, Mallya SM. Cyclin D1 and cyclin D-dependent kinases enhance oral keratinocyte proliferation but do not block keratinocyte differentiation. *Int J Oncol.* 2010; 37(6):1471-5.
- [17] Vora HH, Shah NG, Trivedi TT, Choksi TJ, Chikhlikar PR, Patel DD, et al. Cyclin D1 expression in prediction of survival in carcinoma of the tongue. *GCRI Bulletin.* 1997; 7:130-5.
- [18] Border AC 1970 " Squamous cell epithelioma of the lip". *J AM Med Asso.* 1970; 74: 656-64.
- [19] Loeb LA, et al. Smoking and lung cancer an overview. *Cancer Res.* 1994; 44:5940-58.
- [20] International agency of Research on Cancer. "Monographs on the evaluation of the carcinogenic risk of chemicals to humans". *IARC.* 1986: 38:1-421.
- [21] Wary KK and Sharan RN. "Aqueous extracts of betel nut of north east India induces DNA strand breaks and enhances rate of cell proliferation invitro." *J Cancer Res Clin Oncol.* 1988; 114:579-82.
- [22] Cullen JW, et al. "Health consequences of using smokeless tobacco: Summary of advisory report to the surgeon general" *Public Health Rep.* 1986; 101:355-73.
- [23] Dave BJ, Trivedi AH and Siddarth G. "Role of Arecanut consumption in the cause of oral cancers". *Cancer.* 1992; 70:1017-23.
- [24] Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. *Mol Carcinogenesis.* 1993;7:139-46.
- [25] Donnellan R, Chetty R. Cyclin D1 and human neoplasia. *J Clin Pathol.* 1998; 51:1-7.
- [26] Michalides RJAM, Veelen NMJ, Kristel PMP, Hart AAM, Loftus BM, Hilgers FJM et al. Overexpression of Cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head and Neck Surg.* 1997; 123: 497-502.
- [27] Naitoh H, Shibata S, Kawaguchi A, Kodama M, Mattori T. Overexpression and localization of Cyclin D1 mRNA and antigen in esophageal cancer. *Am J Pathol.* 1995; 46:1161-9.
- [28] Bartkova J, Lukas J, Staurs M, Barlek J. The Prad-1 / Cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. *Int J Cancer.* 1994; 58:568-73.
- [29] Weinstein IB, Zhou P. Cell cycle control gene defects and human cancer. *Encyclopedia of Cancer.* 1997; 1: 256-67.
- [30] Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, et al. Beta-Catenin, a novel prognostic marker for breast cancer: Its roles in Cyclin D1 expression and cancer progression. *97: 4262-6.*
- [31] Bartkova J, Lukas J, Muller H, Lutzhogt D, Strauss M, Barlek J. Cyclin D1 protein expression and function in human breast cancer. *Int J Cancer.* 1994; 57:353-61.
- [32] Akervall JA, Michalides RJ, Mineta H, Balma A, Borg A, Dictor MR, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 over expression. *Cancer.* 1997; 79:380-9.
- [33] Vicente JCD, Zapatero AH, Frerno MF, Lopez AJS. Expression of Cyclin D1 and ki-67 in squamous cell carcinoma of the oral cavity: Clinicopathological and prognostic significance. *Oral Oncol.* 2002; 38:301-8.
- [34] Maahs GS, Machado DC, Neto EAJ, Michaelsen VS. Cyclin D1 expression and cervical metastases in squamous cell carcinoma of the mouth. *Rev Bras Otorrinolaringol.* 2007; 73(1):93-100.

- [35] Sheyn I, Noffsinger AE, Heffelginger S, Davis B, Miller MA. Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinoma. *Human Pathol.* 1997; 28:270-6.
- [36] Gillet C, Smith P, Gregory W, Richards M, Millis R, et al. Cyclin D1 and prognosis in human breast cancer. *Int J Cancer.* 1996;69:92-9
- [37] Lam KY, Irene OL, Yuen APW, Kwong DLW, William W. Cyclin D1 expression in oral squamous cell carcinomas: Clinicopathological relevance and correlation with p53 expression. *J Oral Pathol Med.* 2000; 29:167-72.
- [38] Shintani S, Mihara M, Nakahara Y, Kiyota A, Yegama Y, Matsumura T, et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. *Oral Oncol.* 2002; 38:235-43.
- [39] Goto H, Kawano K, Kobayashi I, Sakai H, Yanagisawa S. Expression of Cyclin D1 and GSK-3 and their predictive value of prognosis in squamous cell carcinomas of the tongue. *Oral Oncol.* 2002; 38:549-56.
- [40] Rousseau A, Lim MS, Lin Z, Jordan RCK. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. *Oral Oncol.* 2001;37:268-75.
- [41] Castle JT, Cardinali M, Kratochvil FJ, Abbondanzo SL., Kessler HP, Aucair P L, et al. P53 and Cyclin D1 staining patterns of malignant and premalignant oral lesions in age dependent populations. *Oral Surg Oral Med Oral Radiol Endod.* 1999; 88: 326-32.
- [42] Minetaa H, Miurab K, Takebayashia S, Uedaa Y, Misawaa K, Haradab H, et al. Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. *Oral Oncol.* 2000; 36:194-8.

**PARTICULARS OF CONTRIBUTORS:**

1. Professor and Head of Department, Department of Oral Pathology & Microbiology, H.K.E.'s S. Nijalingappa Institute of Dental sciences & Research Center, Gulbarga.
2. Post Graduate Student, Department of Oral Pathology & Microbiology, H.K.E.'s S. Nijalingappa Institute of Dental sciences & Research Center, Gulbarga.
3. Professor, Department of Oral Pathology & Microbiology, H.K.E.'s S. Nijalingappa Institute of Dental sciences & Research Center, Gulbarga.

**NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:**

Dr. Maharudrappa Basnaker,  
Professor and Head of Department, Department of Oral Pathology & Microbiology,  
H.K.E.'s S. Nijalingappa Institute of Dental sciences & Research Center, Gulbarga.  
Phone: 09448104721, E-mail: drmhbasnaker@gmail.com

Date of Submission: **Mar 28, 2014**Date of Peer Review: **Apr 17, 2014**Date of Acceptance: **Apr 20, 2014**Date of Publishing: **May 15, 2014****FINANCIAL OR OTHER COMPETING INTERESTS:** None.